2024
The association between naloxone claims and proportion of independent versus chain pharmacies: A longitudinal analysis of naloxone claims in the United States
Freibott C, Jalali A, Murphy S, Walley A, Linas B, Jeng P, Bratberg J, Marshall B, Zang X, Green T, Morgan J. The association between naloxone claims and proportion of independent versus chain pharmacies: A longitudinal analysis of naloxone claims in the United States. Journal Of The American Pharmacists Association 2024, 64: 102093. PMID: 38604474, PMCID: PMC11402586, DOI: 10.1016/j.japh.2024.102093.Peer-Reviewed Original ResearchNaloxone dispensing ratesChain pharmaciesDispensing ratesNaloxone dispensingIndependent pharmaciesUrban-rural classificationNaloxone access lawsLongitudinal analysisAccess lawsOpioid mortality ratesRates of naloxoneUrban/rural designationCounty typesNaloxone availabilityPrimary exposurePrimary outcomeNational studyCounty-levelPharmacyQuarter-yearTwo-sample t-testPopulation characteristicsCo-prescribedSymphony HealthT-test
2023
Research Priorities for Expansion of Opioid Use Disorder Treatment in the Community Pharmacy
Jarrett J, Bratberg J, Burns A, Cochran G, DiPaula B, Dopp A, Elmes A, Green T, Hill L, Homsted F, Hsia S, Matthews M, Ghitza U, Wu L, Bart G. Research Priorities for Expansion of Opioid Use Disorder Treatment in the Community Pharmacy. Substance Abuse 2023, 44: 264-276. PMID: 37902032, PMCID: PMC10870734, DOI: 10.1177/08897077231203849.Peer-Reviewed Original ResearchConceptsOpioid use disorderNational Drug Abuse Treatment Clinical Trials NetworkOUD treatmentCommunity pharmaciesDrug Abuse's National Drug Abuse Treatment Clinical Trials NetworkUse disordersOpioid use disorder treatmentFifth of peoplePrimary care settingBenefits of medicationsClinical Trials NetworkUse disorder treatmentHealth service modelClinical service provisionOpioid overdose crisisPatient populationCommunity pharmacy sectorPatient outcomesCare settingsMOUD servicesDisorder treatmentSynthetic opioidsChain pharmaciesTrials NetworkMOUD
2021
Expanding access to methadone treatment in Ohio through federally qualified health centers and a chain pharmacy: A geospatial modeling analysis
Iloglu S, Joudrey PJ, Wang EA, Thornhill TA, Gonsalves G. Expanding access to methadone treatment in Ohio through federally qualified health centers and a chain pharmacy: A geospatial modeling analysis. Drug And Alcohol Dependence 2021, 220: 108534. PMID: 33497963, PMCID: PMC7901120, DOI: 10.1016/j.drugalcdep.2021.108534.Peer-Reviewed Original ResearchConceptsFederally Qualified Health CentersOpioid treatment programsOpioid use disorderQualified health centersProportion of needHealth centersZip codesTreatment needsMethadone provisionChain pharmaciesRural-Urban Commuting Area codesProvision of methadoneOpioid overdose deathsRural classificationDrive timeMethadone administrationPrimary outcomeOUD treatmentMethadone treatmentUrban-rural strataOverdose deathsUse disordersTreatment programGeospatial modeling analysisOne-third
2020
Pharmacy-based methadone dispensing and drive time to methadone treatment in five states within the United States: A cross-sectional study
Joudrey PJ, Chadi N, Roy P, Morford KL, Bach P, Kimmel S, Wang EA, Calcaterra SL. Pharmacy-based methadone dispensing and drive time to methadone treatment in five states within the United States: A cross-sectional study. Drug And Alcohol Dependence 2020, 211: 107968. PMID: 32268248, PMCID: PMC7529685, DOI: 10.1016/j.drugalcdep.2020.107968.Peer-Reviewed Original ResearchOpioid treatment programsMethadone accessOpioid use disorderCross-sectional studyOpioid overdose deathsCensus tractsDrive timeRural census tractsMethadone treatmentOverdose deathsUse disordersLong drive timesMethadoneTreatment programChain pharmaciesTractMedian differenceRural censusHigh ratePharmacyMedianUnited StatesPopulation
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply